1 Diarrhoea and constipation were also more common on retatrutide than on placebo
In placebo-controlled trials, severe GI reactions were reported in 1.7% (5 mg), 2.5% (10 mg), and 3.1% (15 mg) of Zepbound-treated patients compared to 1% of placebo-treated patients
These insights should be interpreted with a qualified healthcare provider to understand how your individual genetic background might affect both GLP-1 response and thyroid hormone requirements
It is recommended to verify with your insurance provider whether they cover GLP-1 medications
i vi ph n ang cho con b, thuc c th an ton nu s dng vi liu lng nh
M., Brown-Frandsen, K., Colhoun, H